Nanoform Wins Business Finland Grant of EUR 4.3M for its R&D in Nanoparticle-Enabled Formulation

Nanoform, the medicine performance-enhancing company, announced that it has won a grant of up to 4.3 million euros from Business Finland, the Finnish government organization for innovation funding and trade. The grant represents 50% of the costs associated with Nanoform’s R&D project for nanoparticle-enabled formulation platforms for oral, inhaled, long-acting injectable, and high-concentration subcutaneous injectable drug delivery technologies for next generation medicines. The work is expected to take place during 2024 and 2025.

Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, today announced that it has won a grant of up to 4.3 million euros from Business Finland, the Finnish government organization for innovation funding and trade. The grant represents 50% of the costs associated with Nanoform’s research and development project for nanoparticle-enabled formulation platforms for oral, inhaled, long-acting injectable, and high-concentration subcutaneous injectable drug delivery technologies for next generation medicines. The work is expected to take place during 2024 and 2025.

Nanoform has established a unique capability to consistently manufacture particles at less than 100 nanometers, and has developed a deep understanding of nanoparticle interactions, and their performance in pharmaceutical formulations. This grant gives an opportunity to generate deep knowledge about nanoparticle behavior in formulation- and pharmaceutical sciences and to create new intellectual property.

“Combining our unique manufacturing capabilities with a deep and growing knowledge of nanoparticles and their impact on formulations means that we can leverage APIs in ways not possible with other drug delivery techniques” said Dr. Edward Haeggström, Chief Executive Officer of Nanoform. “Encouraged by the outcome of our recent relative bioavailability study of a novel nanoformulation of enzalutamide and Xtandi®, I’m pleased by Business Finland’s decision to join us in exploring what small can do for pharmaceutical development more broadly.”

For more, please find the original story source here.